1.Mental retardation, hypogonadism, epilepsy, white matter lesions and hyperhomocysteinemia in a family.
Dandan SHANG ; Changhe SHI ; Jie QIN ; Bo SONG ; Yuming XU ; Shilei SUN
Chinese Journal of Medical Genetics 2015;32(1):136-137
Adult
;
Epilepsy
;
genetics
;
Humans
;
Hyperhomocysteinemia
;
genetics
;
Hypogonadism
;
genetics
;
Intellectual Disability
;
genetics
;
Male
;
White Matter
;
pathology
2.Graves' Disease Associated with Klinefelter's Syndrome.
Jong Suk PARK ; Chul Sik KIM ; Joo Young NAM ; Dol Mi KIM ; Soo Jee YOON ; Chul Woo AHN ; Bong Soo CHA ; Sung Kil LIM ; Kyung Rae KIM ; Hyun Chul LEE ; Kap Bum HUH
Yonsei Medical Journal 2004;45(2):341-344
Klinefelter's syndrome is one of the most common forms of primary hypogonadism and infertility in males. It is characterized by small and firm testes, gynecomastia, azoospermia, and an elevated gonadotropin level. The frequencies of diabetes mellitus, breast cancer, and germ cell neoplasia increases in Klinefelter's syndrome. We report upon a 35 year-old male patient with Graves' disease in association with Klinefelter's syndrome; as confirmed by chromosome analysis. The patient is being treated with antithyroid medication for Graves' disease and by testosterone replacement for Klinefelter's syndrome.
Adult
;
Graves' Disease/*etiology/radionuclide imaging
;
Human
;
Hypogonadism/*etiology/genetics/pathology
;
Klinefelter Syndrome/*complications/genetics/pathology
;
Male
3.Börjeson -Forssman -Lehmann syndrome: A case report.
Langui PAN ; Fei YIN ; Shimeng CHEN ; Juan XIONG ; Fang HE ; Jing PENG
Journal of Central South University(Medical Sciences) 2023;48(2):294-301
Börjeson-Forssman-Lehmann syndrome (BFLS) is a rare X-linked intellectual disability. The main features of the patients include intellectual disability/global developmental delay, characteristic face, anomalies of fingers and toes, hypogonadism, linear skin hyperpigmentation, and tooth abnormalities in female patients, and obesity in male patients. A case of BFLS caused by a novel mutation of PHF6 gene who was treated in the Department of Pediatrics, Xiangya Hospital, Central South University was reported. The 11 months old girl presented the following symptons: Global developmental delay, characteristic face, sparse hair, ocular hypertelorism, flat nasal bridge, hairy anterior to the tragus, thin upper lip, dental anomalies, ankyloglossia, simian line, tapering fingers, camptodactylia, and linear skin hyperpigmentation. The gene results of the second-generation sequencing technology showed that there was a novel heterozygous mutation site c.346C>T (p.Arg116*) of the PHF6 (NM032458.3), variation rating as pathogenic variation. During the follow-up, the patient developed astigmatism, strabismus, awake bruxism, and stereotyped behavior, and the linear skin hyperpigmentation became gradually more evident. The disease is lack of effective therapy so far.
Humans
;
Male
;
Female
;
Child
;
Infant
;
Intellectual Disability/genetics*
;
Mental Retardation, X-Linked/pathology*
;
Obesity/complications*
;
Hypogonadism/pathology*
4.Apoptotic Sertoli cell death in hypogonadic (hgn/hgn) rat testes during early postnatal development.
Mio YAGI ; Katsushi SUZUKI ; Hirotesu SUZUKI
Asian Journal of Andrology 2006;8(5):535-541
AIMTo determine the involvement of apoptotic cell death in postnatal pathogenesis in mutant strain of hypogonadic (hgn/hgn) rats testes. We evaluated the numbers and types of cells undergoing apoptotic cell death.
METHODSTissue sections were stained by the TUNEL method for in situ detection of apoptotic cells, with specific antibodies used as markers of testicular somatic and germ cells.
RESULTSWe found that apoptosis in the hgn/hgn testes during the early postnatal period occurred primarily in Sertoli cells, which should actively proliferate during this stage of differentiation. These findings strongly suggest that the normal allele of hgn is involved in the direct or indirect control of differentiation and proliferation of Sertoli cells.
CONCLUSIONTo our knowledge, this is the first report demonstrating early postnatal apoptosis of Sertoli cells, suggesting that the hgn/hgn rat is a unique model for the study of Sertoli cell deficiency.
Aging ; Animals ; Apoptosis ; Cell Death ; Hypogonadism ; pathology ; In Situ Nick-End Labeling ; Male ; Rats ; Rats, Inbred Strains ; Sertoli Cells ; pathology ; physiology ; Testis ; growth & development ; pathology
5.Androgen and bone mass in men.
Asian Journal of Andrology 2003;5(2):148-154
Androgens have multiple actions on the skeleton throughout life. Androgens promote skeletal growth and accumulation of minerals during puberty and adolescence and stimulate osteoblast but suppress osteoclast function, activity and lifespan through complex mechanisms. Also androgens increase periosteal bone apposition, resulting in larger bone size and thicker cortical bone in men. There is convincing evidence to show that aromatization to estrogens was an important pathway for mediating the action of testosterone on bone physiology. Estrogen is probably the dominant sex steroid regulating bone resorption in men, but both testosterone and estrogen are important in maintaining bone formation.
Aging
;
physiology
;
Androgens
;
metabolism
;
physiology
;
therapeutic use
;
Bone Resorption
;
etiology
;
prevention & control
;
Bone and Bones
;
pathology
;
physiology
;
Estrogens
;
physiology
;
Humans
;
Hypogonadism
;
pathology
;
Male
;
Puberty
;
physiology
;
Testosterone
;
physiology
6.Growth after Hematopoietic Stem Cell Transplantation in Children with Acute Myeloid Leukemia.
Seung Joon CHUNG ; Seung Wan PARK ; Min Kyoung KIM ; Min Jae KANG ; Young Ah LEE ; Seong Yong LEE ; Choong Ho SHIN ; Sei Won YANG ; Hyoung Jin KANG ; Kyung Duk PARK ; Hee Young SHIN ; Hyo Seop AHN
Journal of Korean Medical Science 2013;28(1):106-113
Previous studies have shown that hematopoietic stem cell transplantation (HSCT) may result in growth impairment. The purpose of this study was to evaluate the growth during 5 yr after HSCT and to determine factors that influence final adult height (FAH). We retrospectively reviewed the medical records of acute myeloid leukemia (AML) patients who received HSCT. Among a total of 37 eligible patients, we selected 24 patients who began puberty at 5 yr after HSCT (Group 1) and 19 patients who reached FAH without relapse (Group 2). In Group 1, with younger age at HSCT, sex, steroid treatment, hypogonadism and hypothyroidism were not significantly associated with growth impairment 5 yr after HSCT. History of radiotherapy (RT) significantly impaired the 5 yr growth after HSCT. Chronic graft-versus-host disease (cGVHD) only temporarily impaired growth after HSCT. In Group 2, with younger age at HSCT, steroid treatment and hypogonadism did not significantly reduce FAH. History of RT significantly reduced FAH. Growth impairment after HSCT may occur in AML patients, but in patients without a history of RT, growth impairment seemed to be temporary and was mitigated by catch-up growth.
Adolescent
;
Body Height/*radiation effects
;
Child
;
Child, Preschool
;
Female
;
Graft vs Host Disease/pathology/prevention & control
;
*Hematopoietic Stem Cell Transplantation
;
Humans
;
Hypogonadism/drug therapy/pathology
;
Infant
;
Leukemia, Myeloid, Acute/radiotherapy/*therapy
;
Male
;
Recurrence
;
Retrospective Studies
;
Risk Factors
;
Steroids/therapeutic use
7.Effects of Saikokaryukotsuboreito on Spermatogenesis and Fertility in Aging Male Mice.
Zhi-Jun ZANG ; Su-Yun JI ; Ya-Nan ZHANG ; Yong GAO ; Bin ZHANG
Chinese Medical Journal 2016;129(7):846-853
BACKGROUNDAspermia caused by exogenous testosterone limit its usage in late-onset hypogonadism (LOH) patients desiring fertility. Saikokaryukotsuboreito (SKRBT) is reported to improve serum testosterone and relieve LOH-related symptoms. However, it is unclear whether SKRBT affects fertility. We aimed to examine the effects of SKRBT on spermatogenesis and fertility in aging male mice.
METHODSThirty aging male mice were randomly assigned to three groups. Mice were orally administered with phosphate-buffer solution or SKRBT (300 mg/kg, daily) or received testosterone by subcutaneous injections (10 mg/kg, every 3 days). Thirty days later, each male mouse was mated with two female mice. All animals were sacrificed at the end of 90 days. Intratesticular testosterone (ITT) levels, quality of sperm, expression of synaptonemal complex protein 3 (SYCP3), and fertility were assayed.
RESULTSIn the SKRBT-treated group, ITT, quality of sperm, and expression of SYCP3 were all improved compared with the control group (ITT: 85.50 ± 12.31 ng/g vs. 74.10 ± 11.45 ng/g, P = 0.027; sperm number: [14.94 ± 4.63] × 106 cells/ml vs. [8.79 ± 4.38] × 106 cells/ml, P = 0.002; sperm motility: 43.16 ± 9.93% vs. 33.51 ± 6.98%, P = 0.015; the number of SYCP3-positive cells/tubule: 77.50 ± 11.01 ng/ml vs. 49.30 ± 8.73 ng/ml, P < 0.001; the expression of SYCP3 protein: 1.23 ± 0.09 vs. 0.84 ± 0.10, P < 0.001), but fertility was not significantly changed (P > 0.05, respectively). In the testosterone-treated group, ITT, quality of sperm, and expression of SYCP3 were markedly lower than the control group (ITT: 59.00 ± 8.67, P = 0.005; sperm number: [4.34 ± 2.45] × 106 cells/ml, P = 0.018; sperm motility: 19.53 ± 7.69%, P = 0.001; the number of SYCP3-positive cells/tubule: 30.00 ± 11.28, P < 0.001; the percentage of SYCP3-positive tubules/section 71.98 ± 8.88%, P = 0.001; the expression of SYCP3 protein: 0.71 ± 0.09, P < 0.001), and fertility was also suppressed (P < 0.05, respectively).
CONCLUSIONSKRBT had no adverse effect on fertility potential in aging male mice.
Aging ; Animals ; Drugs, Chinese Herbal ; pharmacology ; Fertility ; drug effects ; Hypogonadism ; drug therapy ; Male ; Mice ; Nuclear Proteins ; analysis ; Sperm Count ; Sperm Motility ; drug effects ; Spermatogenesis ; drug effects ; Testis ; drug effects ; pathology ; Testosterone ; blood
8.Evaluation of gonadotropin-replacement therapy in male patients with hypogonadotropic hypogonadism.
Mazhar ORTAC ; Muhammed HIDIR ; Emre SALABAS ; Abubekir BOYUK ; Caner BESE ; Yasar PAZIR ; Ates KADIOGLU
Asian Journal of Andrology 2019;21(6):623-627
Hypogonadotropic hypogonadism (HH) is a rare disease in which medical treatment has a high success rate to achieve fertility. This study aimed to analyze the efficacy of hormone replacement therapy and determine predictive factors for successful spermatogenesis and spontaneous pregnancy in patients with idiopathic HH. A total of 112 patients with low testosterone (T), luteinizing hormone (LH) and follicle-stimulating hormone (FSH), and normal prolactin levels were diagnosed with HH and administered LH and FSH analogs as hormone replacement therapy. During treatment, 96 (85.7%) patients had sperm present in ejaculate samples. Among these patients, 72 were married and wanted a child. Of these 72 patients, 48 (66.7%) of couples had pregnancies from natural conception. After initiation of treatment, the mean time for the appearance of sperm in semen was 9.48 months. There were no significant differences between baseline FSH, T, and LH levels; however, older age, larger testicular size, and low rate of undescended testes were favorable factors for successful spermatogenesis. Larger testicular size and older age were also the main predictive factors for natural conception. We found that patients with undescended testes had a younger age, smaller testes, and lower T levels compared with patients exhibiting descended testes. The rate of sperm found in the ejaculate was not significantly decreased in patients with undescended compared with descended testis (73.7% vs 87.6%, P = 0.261). The medical approach for males with HH and azoospermia provides a successful treatment modality in regard to successful spermatogenesis and achievement of pregnancy.
Adolescent
;
Adult
;
Chorionic Gonadotropin/therapeutic use*
;
Follicle Stimulating Hormone/therapeutic use*
;
Gonadotropins/therapeutic use*
;
Hormone Replacement Therapy/methods*
;
Humans
;
Hypogonadism/pathology*
;
Luteinizing Hormone/therapeutic use*
;
Male
;
Middle Aged
;
Retrospective Studies
;
Spermatogenesis/drug effects*
;
Young Adult
9.Predictive factors for pituitary response to pulsatile GnRH therapy in patients with congenital hypogonadotropic hypogonadism.
Jiang-Feng MAO ; Xi WANG ; Jun-Jie ZHENG ; Zhao-Xiang LIU ; Hong-Li XU ; Bing-Kun HUANG ; Min NIE ; Xue-Yan WU
Asian Journal of Andrology 2018;20(4):319-323
Pulsatile gonadotropin-releasing hormone (GnRH) may induce spermatogenesis in most patients with congenital hypogonadotropic hypogonadism (CHH) by stimulating gonadotropin production, while the predictors for a pituitary response to pulsatile GnRH therapy were rarely investigated. Therefore, the aim of our study is to investigate predictors of the pituitary response to pulsatile GnRH therapy. This retrospective cohort study included 82 CHH patients who received subcutaneous pulsatile GnRH therapy for at least 1 month. Patients were categorized into poor or normal luteinizing hormone (LH) response subgroups according to their LH level (LH <2 IU l-1 or LH ≥2 IU l-1) 1 month into pulsatile GnRH therapy. Gonadotropin and testosterone levels, testicular size, and sperm count were compared between the two subgroups before and after GnRH therapy. Among all patients, LH increased from 0.4 ± 0.5 IU l-1 to 7.5 ± 4.4 IU l-1 and follicle-stimulating hormone (FSH) increased from 1.1 ± 0.9 IU l-1 to 8.8 ± 5.3 IU l-1. A Cox regression analysis showed that basal testosterone level (β = 0.252, P = 0.029) and triptorelin-stimulated FSH60min(β = 0.518, P = 0.01) were two favorable predictors for pituitary response to GnRH therapy. Nine patients (9/82, 11.0%) with low LH response to GnRH therapy were classified into the poor LH response subgroup. After pulsatile GnRH therapy, total serum testosterone level was 39 ± 28 ng dl-1 versus 248 ± 158 ng dl-1 (P = 0.001), and testicular size was 4.0 ± 3.1 ml versus 7.9 ± 4.5 ml (P = 0.005) in the poor and normal LH response subgroups, respectively. It is concluded that higher levels of triptorelin-stimulated FSH60minand basal total serum testosterone are favorable predictors of pituitary LH response to GnRH therapy.
Adult
;
Cohort Studies
;
Follicle Stimulating Hormone/blood*
;
Gonadotropin-Releasing Hormone/therapeutic use*
;
Gonadotropins/blood*
;
History, 16th Century
;
Humans
;
Hypogonadism/pathology*
;
Luteinizing Hormone/blood*
;
Male
;
Pituitary Gland/pathology*
;
Predictive Value of Tests
;
Retrospective Studies
;
Sperm Count
;
Testis/pathology*
;
Testosterone/blood*
;
Treatment Outcome
;
Triptorelin Pamoate/therapeutic use*
;
Young Adult
10.Secondary male hypogonadism induced by sellar space-occupying lesion: Clinical analysis of 22 cases.
Hong-Lei LU ; Tao WANG ; Hao XU ; Li-Ping CHEN ; Ke RAO ; Jun YANG ; Hui-Xing YUAN ; Ji-Hong LIU
National Journal of Andrology 2016;22(8):704-709
ObjectiveTo analyze the clinical characteristics of secondary male hypogonadism induced by sellar space-occupying lesion, explore its pathogenesis, and improve its diagnosis and treatment.
METHODSWe retrospectively analyzed the clinical data about 22 cases of secondary male hypogonadism induced by sellar space-occupying lesion, reviewed related literature, and investigated the clinical manifestation, etiological factors, and treatment methods of the disease. Hypogonadism developed in 10 of the patients before surgery and radiotherapy (group A) and in the other 12 after it (group B). The patients received endocrine therapy with Andriol (n=7) or hCG (n=15).
RESULTSThe average diameter of the sellar space-occupying lesions was significantly longer in group A than in B ([2.35±0.71] vs [1.83±0.36] cm, P<0.05) and the incidence rate of prolactinomas was markedly higher in the former than in the latter group (60% vs 0, P<0.01). The levels of lutein hormone (LH), follicle stimulating hormone (FSH) and testosterone (T) were remarkably decreased in group B after surgery and radiotherapy (P<0.01). Compared with the parameters obtained before endocrine therapy, all the patients showed significant increases after intervention with Andriol or hCG in the T level ([0.78±0.40] vs [2.71±0.70] ng/ml with Andriol; [0.93±0.44] vs [3.07±0.67] ng/ml with hCG) and IIEF-5 score (5.00±2.61 vs 14.50±3.62 with Andriol; 5.36±1.82 vs 15.07±3.27 with hCG) (all P<0.01). The testis volume increased and pubic hair began to grow in those with hypoevolutism. The patients treated with hCG showed a significantly increased testis volume (P<0.01) and sperm was detected in 7 of them, whose baseline testis volume was markedly larger than those that failed to produce sperm ([11.5±2.3] vs [7.5±2.3] ml, P<0.01). Those treated with Andriol exhibited no significant difference in the testis volume before and after intervention and produced no sperm, either.
CONCLUSIONSHypothyroidism might be attributed to surgery- or radiotherapy-induced damage to the pituitary tissue, space-occupying effect of sellar lesion, and hyperprolactinemia. Both Andriol and hCG can improve the T level and erectile function, but the former does not help spermatogenesis.
Adult ; Chorionic Gonadotropin ; therapeutic use ; Follicle Stimulating Hormone ; blood ; Humans ; Hypogonadism ; diagnosis ; etiology ; therapy ; Luteinizing Hormone ; blood ; Male ; Pituitary Neoplasms ; blood ; complications ; pathology ; therapy ; Prolactinoma ; blood ; complications ; pathology ; therapy ; Retrospective Studies ; Sella Turcica ; Spermatogenesis ; Spermatozoa ; Testis ; anatomy & histology ; drug effects ; Testosterone ; analogs & derivatives ; blood ; therapeutic use ; Tumor Burden